Search results
Results from the WOW.Com Content Network
PDUFA date. In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application. [1] It is part of the regime established by the Prescription Drug User Fee Act to ensure funding of the Food and ...
In United States pharmaceutical regulatory practice, a Complete Response Letter (CRL), or more rarely, a 314.110 letter, is a regulatory action by the Food and Drug Administration in response to a New Drug Application, Amended New Drug Application or Biologics License Application, indicating that the application will not be approved in its present form.
New Drug Application. The Food and Drug Administration 's (FDA) New Drug Application ( NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. [ 1][ 2] Some 30% or less of initial drug candidates proceed through the entire multi-year process of drug ...
The company's lead product, Gattex ® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent ...
An Abbreviated New Drug Application ( ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug . The ANDA is submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, which provides for the review and ultimate approval of a generic drug product.
In the theme of Christmas and the spirit of giving, I plan to use the next two weeks leading up to Christmas to countdown the 12 Days of Christmas in all its Foolish glory. In my rendition of this ...
1987 In May, the FDA approved the "first formulation of an opioid pain medicine that allowed dosing every 12 hours instead of every 4 to 6 hours"—MS Contin, morphine sulfate. [1] In 1995, Purdue Pharma laboratory tests showed that "68% of the oxycodone could be extracted from an OxyContin tablet when crushed". [10] [11]
In its Q4 and 2012 results today, Novartis announced that net sales grew 2% year-over-year on a constant currency basis to $14.8 billion during the quarter, while net income advanced 5% to $3.1 ...